Recombinant Human Chymotrypsin(OsrhCT)

Phase 2Small molecule

Recombinant Human Chymotrypsin(OsrhCT) is one of 89 small molecule programs targeting Hypoalbuminemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoalbuminemiaActive, not recruiting

Efficacy and SafetyActive, not recruiting

EfficacyNot yet recruiting

HypoalbuminemiaPreclinical

Active, not recruiting

Efficacy and SafetyPhase 2

Active, not recruiting

EfficacyPhase 1

Not yet recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

4 2

Romiplostim N01

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 3

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 3

1 4

Imlifidase

HHansa Biopharma AB

Phase 3

2 5

INZ-701

IInozyme Pharma

Phase 3

1 6

IBI302

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 7

IN-B00009

HHK inno.N Corporation

Phase 3

1 8

Lenzumestrocel

CCorestemchemon, Inc.

Phase 3

1 9

VSA003

VVisirna Therapeutics HK Limited

Phase 3

1 10

Onglyza

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Hypoalbuminemia

NCT07435922

Clinical

Trials by Indication[1]

Hypoalbuminemia1 trial

Evaluate Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment

Not yet recruiting·HHealthgen Biotechnology Corp.··NCT07435922·2,000 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

Active, not recruiting·HHealthgen Biotechnology Corp.·Phase 2·NCT06722664·336 enrolled

Efficacy1 trial

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy

Not yet recruiting·HHealthgen Biotechnology Corp.·Phase 1·NCT06525272·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Recombinant Human Chymotrypsin(OsrhCT). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Human Chymotrypsin(OsrhCT) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Human Chymotrypsin(OsrhCT). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healthgen Biotechnology Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHealthgen Biotechnology Corp.

Recombinant Human Chymotrypsin(OsrhCT)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hypoalbuminemia1 trial

Efficacy and Safety1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News